---
title: Safety and Effects of Ramipril Combined With Candesartan
nct_id: NCT00356395
overall_status: COMPLETED
phase: PHASE4
sponsor: Gachon University Gil Medical Center
study_type: INTERVENTIONAL
primary_condition: Hypertension
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00356395.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00356395"
ct_last_update_post_date: 2006-07-26
last_seen_at: "2026-05-12T06:26:41.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Safety and Effects of Ramipril Combined With Candesartan

**Official Title:** Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients

**NCT ID:** [NCT00356395](https://clinicaltrials.gov/study/NCT00356395)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 40
- **Lead Sponsor:** Gachon University Gil Medical Center
- **Conditions:** Hypertension
- **Start Date:** 2003-08
- **Completion Date:** 2006-03
- **CT.gov Last Update:** 2006-07-26

## Brief Summary

we hypothesized that combination therapy has additive beneficial effects to improve endothelial dysfunction and adipocytokine profiles in patients with hypertension.

## Detailed Description

Forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16 mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled cross-over trial with three treatment arms and two washout periods (each 2 months).

## Eligibility

- **Minimum age:** 35 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* patients with mild to moderate hypertension

Exclusion Criteria:

* We will exclude patients with severe hypertension, unstable angina, acute myocardial infarction, or renal insufficiency.
```

## Interventions

- **ramipril, candesartan** (DRUG)

## Primary Outcomes

- **comparison of endothelium-dependent dilation among the 3 treatment schemes**

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00356395.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00356395*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*